Browse Technologies

Displaying 1 - 2 of 2


Novel anti-platelet therapy for treatment of thrombosis, cardiovascular disease, and cerebrovascular injury

One of the leading causes of deaths in developed countries is related to thromboembolism. PAR-4 (protease activated receptor-4) is one of two receptors on the human platelet that respond to thrombin, the central enzyme of coagulation.  Researchers here at Vanderbilt University have developed novel antagonists of PAR-4 that could be beneficial for patients allowing for normal hemostasis during treatment for thrombotic events.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Cardiovascular

Long-Lasting and Self-Sustaining Cell Therapy System

Researchers at Vanderbilt have created a novel drug delivery system using two distinct T-cell populations that interact to promote engraftment and persistence in pre-clinical models, increasing the efficacy of T-cell therapies. Furthermore, "booster" treatments can be administered months after the first dose to produce an expansion of antigen specific T cells. These advantages result in longer-term therapeutic efficacy and could reduce the number of treatments required. This system also represents a viable self-renewing platform for the delivery of biologic drugs in patients who would otherwise require frequent administration.


Licensing Contact

Cameron Sargent

615.322.5907